EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access

Quinoline‐Based Scaffolds in Anticancer Drug Discovery: Molecular Targets, Synthetic Strategies, and Biological Advances

Amir Raza iD, Pankaj Wadhwa iD, Shivani Sharma iD

ChemMedChem · 2026-09-14 · 21 (17)

DOI: 10.1002/cmdc.70472 ↗

At a glance

Übersichtsarbeit in ChemMedChem, published online on 2026-08-27. Written by Amir Raza and 2 co-authors. Institution: School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India. Major MEDLINE topics: Antineoplastic Agents, Quinolines, Drug Discovery, Neoplasms. Cited 2 times so far (Crossref); 167 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Cancer remains a major global health challenge, and the limited efficacy, systemic toxicity, multidrug resistance, and tumor recurrence associated with current therapies continue to drive the development of novel targeted anticancer agents. Quinoline‐based heterocyclic scaffolds have emerged as valuable structural frameworks in anticancer drug discovery owing to their structural diversity and ability to interact with multiple oncogenic targets. This review provides a target‐oriented overview of quinoline‐based anticancer agents reported between 2019 and 2025, covering quinoline, quinazoline, quinoxaline, and a few selected nonquinoline nitrogen‐containing heterocyclic derivatives. Recent advances in quinoline‐based derivatives targeting ER, CDK4/6, topoisomerase I/II, epidermal growth factor receptor, PLCγ1, PI3K/AKT, and VEGFR‐2/P‐glycoprotein pathways are discussed with respect to their synthetic strategies, in vitro anticancer assay, and structure–activity relationships (SAR). This review integrates comparative SAR trends across diverse quinoline‐based scaffolds, highlighting the influence of scaffold planarity, ring fusion, substitution patterns, linker architecture, and metal complexation on anticancer activity. In addition, clinically approved quinoline‐based anticancer drugs, representative patents, and future perspectives are summarized to emphasize the translational potential of these scaffolds. Collectively, this review provides a comprehensive overview of recent advances to guide the rational design of next‐generation quinoline‐based anticancer agents.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsQuinolinesDrug DiscoveryNeoplasmsHumansStructure-Activity RelationshipMolecular StructureAnimals

Author keywords

anticancer agentsquinazoline derivativesquinoline derivativesquinoxaline derivativesstructure–activity relationshiptargeted anticancer therapy

Substances

Antineoplastic AgentsQuinolinesquinoline

Authors and institutions

  • School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
  • CT College of Pharmacy, CT Group of Institutions, Jalandhar, Punjab, India.
  • Ummeed Institute of Pharmaceutical Sciences and Research Centre, Sri Ganganagar, Rajasthan, India.

ORCID profiles: Amir Raza, Pankaj Wadhwa, Shivani Sharma

Cite

APA

Raza, A., Wadhwa, P., & Sharma, S. (2026). Quinoline‐Based Scaffolds in Anticancer Drug Discovery: Molecular Targets, Synthetic Strategies, and Biological Advances. ChemMedChem, 21(17). https://doi.org/10.1002/cmdc.70472

Vancouver

Raza A, Wadhwa P, Sharma S. Quinoline‐Based Scaffolds in Anticancer Drug Discovery: Molecular Targets, Synthetic Strategies, and Biological Advances. ChemMedChem. 2026;21(17). doi:10.1002/cmdc.70472

BibTeX
@article{Raza2026,
  author = {Raza, Amir and Wadhwa, Pankaj and Sharma, Shivani},
  title = {Quinoline‐Based Scaffolds in Anticancer Drug Discovery: Molecular Targets, Synthetic Strategies, and Biological Advances},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {17},
  doi = {10.1002/cmdc.70472}
}
Start for free →